ISTANBUL British drug maker GSK on Monday said it will buy US biopharmaceutical company IDRx for up to $1.15 billion. The Boston-based biotechnology firm is developing therapeutics for the treatment of gastrointestinal stromal tumors. GSK will make a $1 billion upfront payment, with the possibility of a $150 million follow-on milestone payments. "This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical need,

Tag-uri: GSK